CUV — Clinuvel Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$381.23m
- AU$131.12m
- AU$94.02m
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist
Australia's Clinuvel Pharmaceuticals slips after Jefferies cuts target price on trial setback
Brief: Clinuvel Pharmaceuticals Says FDA Relaxes Scenesse Postmarketing Requirement
Brief: Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo Study
Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales
Australia's Clinuvel Pharmaceuticals falls on weak HY profit
Brief: Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 Million
Australia's Clinuvel Pharmaceuticals jumps on preclinical study of peptide platform
Brief: Clinuvel Pharmaceuticals Expands Singapore Rd&I Centre To Pioneer Next-Generation Peptide Therapies
Australia's Clinuvel jumps on expansion of Singapore R&D hub
Australia's Clinuvel Pharmaceuticals falls as US shutdown delays SEC filings
Brief: Clinuvel Pharmaceuticals Expects U.S. Shutdown To Impact SEC Review Timelines
Brief: Clinuvel Pharmaceuticals Announces Philippe Wolgen Resumes Duties As CEO
Brief: Clinuvel Pharmaceuticals Posts FY Net Income Of A$36.2 Million
Brief: Clinuvel Pharmaceuticals Preparing Upgrade Of ADR Program To Level II, Nasdaq Uplist
Morningstar flags market pessimism on Aussie co Clinuvel's drug rollout